Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical Trial Results - Progress in Cancer Care

These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.

The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.

  • Zoledronic Acid Did Not Improve Disease-Free Survival in Breast Cancer
    (Posted: 12/27/2010, Updated: 10/20/2011) - The addition of zoledronic acid to standard adjuvant therapy did not extend disease-free survival for women with stage II or III breast cancer in the phase III AZURE trial, results of which were presented at the 2010 San Antonio Breast Cancer Symposium.
  • Treatment Regimen Extends Survival for Women with Cervical Cancer
    (Posted: 06/29/2009, Updated: 10/20/2011) - Patients with locally advanced cervical cancer who received gemcitabine (Gemzar®) both as part of initial treatment and as part of therapy following primary treatment had improved survival compared with patients whose treatment did not include gemcitabine, according to findings presented at the 2009 ASCO meeting in Orlando.
  • Chemotherapy Before Surgery May Increase Survival in Stomach Cancer
    (Posted: 07/09/2007, Updated: 10/19/2011) - Chemotherapy given before surgery for cancer of the lower esophagus and stomach increased the number of patients surviving for five years compared to surgery alone, according to findings presented at the 2007 ASCO meeting in Chicago.
  • NIH-funded study shows increased prostate cancer risk from vitamin E supplements
    (Posted: 10/11/2011) - Men who took 400 international units of vitamin E daily had more prostate cancers compared to men who took a placebo, according to an updated review of data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT). The findings showed that, per 1,000 men, there were 76 prostate cancers in men who took only vitamin E supplements, vs. 65 in men on placebo over a seven-year period, or 11 more cases of prostate cancer per 1,000 men. This represents a 17 percent increase in prostate cancers relative to those who took a placebo. This difference was statistically significant and therefore is not likely due to chance.
  • Nilotinib Effective and Safe in Initial Treatment of Chronic Leukemia
    (Posted: 12/28/2009, Updated: 09/06/2011) - Preliminary results from a phase III trial testing nilotinib (Tasigna) against imatinib mesylate (Gleevec) as first-line treatment for chronic-phase chronic myelogenous leukemia (CML) indicate that nilotinib is effective and safe as initial treatment for this disease.
< Previous  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  Next >